

Sudeep Pharma (SUDEEPPH IN)

Rating: Not Rated | CMP: Rs596 | TP: NA

February 2, 2026

Visit Update

Key Financials - Consolidated

Y/e Mar	FY22	FY23	FY24	FY25
Sales (Rs. m)	3,430	4,287	4,593	5,020
EBITDA (Rs. m)	596	890	1,787	1,783
Margin (%)	17.4	20.8	38.9	35.5
PAT (Rs. m)	424	612	1,294	1,260
EPS (Rs.)	-	-	-	-
Gr. (%)	-	-	-	-
DPS (Rs.)	-	-	-	-
Yield (%)	-	-	-	-
RoE (%)	36.1	32.2	46.0	32.8
RoCE (%)	35.9	33.2	48.8	35.8
EV/Sales (x)	0.2	0.2	0.1	0.2
EV/EBITDA (x)	0.9	0.7	0.3	0.5
PE (x)	-	-	-	-
P/BV (x)	-	-	-	-

Key Data

SUDP.BO | SUDEEPPH IN

52-W High / Low	Rs.795 / Rs.525
Sensex / Nifty	80,723 / 24,825
Market Cap	Rs.67.3bn/ \$ 731.4m
Shares Outstanding	112.9m
3M Avg. Daily Value	Rs.-m

Shareholding Pattern (%)

Promoter's	76.15
Foreign	1.67
Domestic Institution	17.60
Public & Others	4.58
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(0.2)	-	-
Relative	2.2	-	-

Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

Saurabh Ahire

saurabhahire@plindia.com | 91-22-66322537

Tejas Kadam

tejaskadam@plindia.com | 91-22-66322222

Foraying into battery-grade iron phosphate

Quick Pointers:


- Commercial iron phosphate plant to commence operations in early CY27
- New greenfield facility at Nandesari to be commissioned in ~2 months

We visited Sudeep Pharma Ltd's (SUDEEPPH IN) manufacturing facilities at Nandesari to understand its operating capabilities, expansion plans and medium-term growth drivers. The company is in the process of transitioning from a legacy mineral-based pharma and nutrition ingredients player to a technology-driven specialty materials company, led by its entry into battery-grade iron phosphate for LFP applications, alongside steady expansion in pharmaceutical, food and nutrition segments. The company operates 4 manufacturing facilities, which are vertically integrated, where most processes are single step in nature. Calcium carbonate/calcium hydroxide and phosphoric acid are key raw materials used across businesses. Over FY21-25, Sudeep Pharma has delivered sales/EBITDA/PAT CAGR of 13%/40%/41%. The company currently trades at 51x FY25 EPS. We don't have a rating on the stock.

- **Foraying into battery-grade iron phosphate:** Building on over a decade of experience in manufacturing food-grade iron phosphate, the company is now leveraging its core capabilities to enter the battery-grade iron phosphate market, a critical precursor for LFP batteries. Iron phosphate used for LFP applications is anhydrous in nature, requiring iron and phosphoric acid as key inputs. The company currently operates an R&D facility with ~25kg/day capacity and a pilot plant with ~200 kg/day capacity, which has enabled process validation and customer sampling before the commercial comes online.
- **Commercial iron phosphate facility coming up at Dahej:** A commercial greenfield facility is under development at Dahej, with operations expected to commence in early CY27. Phase 1 capacity is planned at 25,000mtpa, scalable to 100,000mtpa in a phased manner, with potential to add another 100,000mtpa over time, in case of strong demand visibility. The company follows a green manufacturing process that eliminates effluent generation and enables reuse of process leftovers, while Chinese peers use ferrous sulphate-based routes, which generate effluents. Initial offtake is expected from South Korea and Europe, while domestic demand for LFP batteries is likely to gain meaningful traction from CY28.
- **Nandesari greenfield plant to be commissioned in ~2 months:** The upcoming greenfield plant at Nandesari is expected to be commissioned over the next ~2 months and will have an installed capacity of 51,200mtpa. The plant will manufacture both legacy products as well as newer, higher value offerings such as gluconates and citrates. Capex incurred for the project stands at ~Rs1.25bn, with asset turnover of ~3x and optimal utilization levels of 70–75% once operational. The facility also houses a dedicated 10,000mtpa unit for infant nutrition products, which commands relatively higher realizations. Manufacturing operations are largely automated, and the plant has adequate land and infrastructure to support future expansions.

- **Technology and forward integration to drive Sudeep Nutrition growth:** We also visited Sudeep Nutrition's specialty segment manufacturing and R&D facility, which commenced operations in FY21. The plant operates across 6 core technologies: granulation, encapsulation, spray drying, trituration, blending and liposomal. The facility provides flexibility depending upon the applications. Minerals are sourced internally from Sudeep Pharma and are forward integrated to enhance value addition, while vitamins and select nutrition inputs are procured externally. Realizations in the specialty business are higher than the core business, making this segment a key margin-accretive growth driver over the medium term.

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
-----	------	--------	----------	-------------------

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Accumulate	401	375
2	Bharat Petroleum Corporation	Accumulate	381	349
3	Bharti Airtel	Accumulate	2,259	2,113
4	Clean Science and Technology	Hold	841	861
5	Deepak Nitrite	Hold	1,729	1,626
6	Fine Organic Industries	BUY	5,103	4,274
7	GAIL (India)	BUY	202	169
8	Gujarat Fluorochemicals	Hold	3,639	3,485
9	Gujarat Gas	Accumulate	422	399
10	Gujarat State Petronet	Hold	296	303
11	Hindustan Petroleum Corporation	Accumulate	457	428
12	Indian Oil Corporation	Accumulate	175	164
13	Indraprastha Gas	Hold	196	190
14	Jubilant Ingrevia	Hold	755	744
15	Laxmi Organic Industries	Reduce	125	143
16	Mahanagar Gas	BUY	1,356	1,074
17	Mangalore Refinery & Petrochemicals	Accumulate	162	151
18	Navin Fluorine International	Accumulate	6,722	5,751
19	NOCIL	Hold	152	148
20	Oil & Natural Gas Corporation	BUY	307	242
21	Oil India	BUY	538	426
22	Petronet LNG	Hold	281	295
23	Reliance Industries	BUY	1,683	1,458
24	SRF	Hold	2,894	2,883
25	Vinati Organics	BUY	1,887	1,615

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com